ADMA Biologics, Inc. (ADMA)
9.545
-0.30
(-3.00%)
USD |
NASDAQ |
Aug 24, 16:00
9.545
0.00 (0.00%)
After-Hours: 20:00
ADMA Biologics Enterprise Value : 2.285B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 2.285B |
| August 20, 2026 | 2.267B |
| August 19, 2026 | 2.333B |
| August 18, 2026 | 2.218B |
| August 17, 2026 | 2.173B |
| August 14, 2026 | 2.202B |
| August 13, 2026 | 2.188B |
| August 12, 2026 | 2.272B |
| August 11, 2026 | 2.300B |
| August 10, 2026 | 2.265B |
| August 07, 2026 | 2.299B |
| August 06, 2026 | 2.335B |
| August 05, 2026 | 2.155B |
| August 04, 2026 | 2.076B |
| August 03, 2026 | 2.037B |
| July 31, 2026 | 1.974B |
| July 30, 2026 | 2.022B |
| July 29, 2026 | 2.031B |
| July 28, 2026 | 2.049B |
| July 27, 2026 | 1.979B |
| July 24, 2026 | 1.932B |
| July 23, 2026 | 1.954B |
| July 22, 2026 | 1.956B |
| July 21, 2026 | 2.004B |
| July 20, 2026 | 2.040B |
| Date | Value |
|---|---|
| July 17, 2026 | 2.031B |
| July 16, 2026 | 2.053B |
| July 15, 2026 | 2.024B |
| July 14, 2026 | 2.067B |
| July 13, 2026 | 2.089B |
| July 10, 2026 | 2.114B |
| July 09, 2026 | 2.157B |
| July 08, 2026 | 2.132B |
| July 07, 2026 | 2.143B |
| July 06, 2026 | 2.132B |
| July 02, 2026 | 2.085B |
| July 01, 2026 | 2.008B |
| June 30, 2026 | 1.954B |
| June 29, 2026 | 2.011B |
| June 26, 2026 | 2.099B |
| June 25, 2026 | 2.092B |
| June 24, 2026 | 2.087B |
| June 23, 2026 | 2.085B |
| June 22, 2026 | 2.057B |
| June 18, 2026 | 1.997B |
| June 17, 2026 | 2.022B |
| June 16, 2026 | 2.059B |
| June 15, 2026 | 2.041B |
| June 12, 2026 | 1.973B |
| June 11, 2026 | 1.999B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Erasca, Inc. | 5.286B |
| Krystal Biotech, Inc. | 9.421B |
| Vericel Corp. | 2.116B |
| Emergent BioSolutions, Inc. | 707.90M |
| Exelixis, Inc. | 12.79B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 37.82M |
| Revenue (Quarterly) | 124.40M |
| Total Expenses (Quarterly) | 86.57M |
| EPS Diluted (Quarterly) | 0.1642 |
| Gross Profit Margin (Quarterly) | 69.31% |
| Profit Margin (Quarterly) | 30.40% |
| Earnings Yield | 7.38% |
| Operating Earnings Yield | 9.46% |
| Normalized Earnings Yield | 7.446 |